Given the preliminary clinical data, combined with a favorable safety and tolerability profile, results support further development of DC-806 in psoriasis and other IL-17-mediated diseases, such as psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. Here, IL17A is linked to psoriasis.